Atezolizumab
Monoclonal antibody
Evidence outlook
Approved: Non-Small Cell Lung Cancer, Colorectal Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Bladder Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (3)
- Alveolar Soft Part Sarcoma (ASPS) for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic ASPS.
- Unresectable, advanced or recurrent non-small cell lung cancer (applicant Chugai)
- Urothelial carcinoma (first listed indication); later extended to NSCLC and other cancers
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
OAK NCT02008227 · Non-Squamous Non-Small Cell Lung Cancer This large randomized, active-controlled Phase 3 trial (1225 patients) compared atezolizumab to docetaxel in advanced NSCLC. The primary endpoint was overall survival, a hard clinical endpoint, and it was met: median OS 13.8 months for atezolizumab vs 9.6 months for docetaxel, HR 0.73 (95% CI 0.62-0.87), p=0.0003. The trial was not blinded (open-label), so despite the robust randomized design and positive result, the evidence is graded moderate rather than strong. Registry: NCT02008227 | 3 | Percentage of Participants Who Died: PP-ITT (Baseline until death due to any cause (up to approximately 2.25 years)); Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP (Baseline until death due to any cause (up to approximately 2.25 years)); Overall Survival (OS): PP-ITT (Baseline until death due to any cause (up to approximately 2.25 years)); OS: TC1/2/3 or IC1/2/3 Subgroup of PP (Baseline until death due to any cause (up to approximately 2.25 years)); OS: SP-ITT (Baseline until death due to any cause (up to approximately 2.87 years)); OS: TC1/2/3 Or IC1/2/3 Subgroup of SP (Baseline until death from any cause (approximately 2.87 years)); OS: TC2/3 or IC2/3 Subgroup of SP (Baseline until death due to any cause (up to approximately 2.87 years)); OS: TC3 or IC3 Subgroup of SP (Baseline until death due to any cause (up to approximately 2.87 years)) 2016-07-07 | Percentage of Participants Who Died: PP-ITT (Baseline until death due to any cause (up to approximately 2.25 years)): Atezolizumab 63.8% vs Docetaxel 70.1% | Partial signal | link ↗ |
View 5 more trials
IMpower150 NCT02366143 · Carcinoma, Non-Small-Cell Lung The study was a large randomized, open-label, active-controlled trial with 1,202 participants and hard clinical endpoints of progression-free and overall survival. Results were mixed across the primary comparisons: the atezolizumab-plus-bevacizumab regimen met its PFS and OS comparisons, but the atezolizumab-without-bevacizumab regimen missed its primary OS comparison, so the overall evidence is moderate rather than strong. Registry: NCT02366143 | 3 | Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)); Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population (Baseline until death until data cut-off on 22 January 2018 (up to approximately 34 months)); Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population (Baseline until death (up approximately 53 months)) 2019-09-13 | Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1) | Partial signal | link ↗ |
NCT03456063 NCT03456063 · Non-Small-Cell Lung The trial randomly assigned 453 participants to double-masked atezolizumab plus chemotherapy or placebo plus chemotherapy, with independent-review event-free survival as a hard clinical primary endpoint. The registry results show the primary analysis did not reach statistical significance (HR 0.77, 95% CI 0.58-1.02, p=0.0704 in the stage IIB-IIIB wild-type population). Registry: NCT03456063 | 3 | Independent Review Facility (IRF)-Assessed Event Free Survival (EFS) (Up to approximately 96 months) 2025-10-01 | IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 | Partial signal | link ↗ |
NCT02486718 NCT02486718 · Non-Small Cell Lung Cancer This was a large randomized phase 3 trial against best supportive care, but it was open-label and disease recurrence was judged by the investigators, who knew which treatment each patient received. Of the three primary disease-free survival analyses, the one in all randomized patients did not reach significance, while the stage II to IIIA and PD-L1 positive subgroups showed a benefit, so the overall result is mixed. Registry: NCT02486718 | 3 | Disease-Free Survival (DFS) in Intent-to-treat (ITT) Population (Up to 95 months); DFS in All Randomized Stage II-IIIA Population (Up to 95 months); DFS in the Programmed Death-ligand 1 (PD-L1) SP263 ≥ 1% Tumor Cell (TC) Subpopulation Within the Stage II-IIIA Population (Up to 95 months) 2024-01-26 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT02409342 NCT02409342 · Non-Small Cell Lung Cancer This was a randomized phase 3 trial against chemotherapy with overall survival as the primary endpoint, a measure that knowing the treatment cannot change. Atezolizumab improved survival in the high PD-L1 group but not in the next group tested, so the result is only partly positive, and the open-label design also keeps it below the top tier. Registry: NCT02409342 | 3 | Overall Survival (OS) in the TC3 or IC3-WT Populations (From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)); Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations (From randomization to death from any cause until data cut-off on 4 February 2020 (up to approximately 54.5 months)) 2020-02-04 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
IMpower130 NCT02367781 · Non-Small Cell Lung Cancer This was a large randomized phase 3 trial against chemotherapy alone, and atezolizumab met both primary endpoints, progression-free and overall survival. Patients and doctors knew which treatment was given, and progression was judged by the treating investigators rather than a blinded central review, so the evidence is solid but not of the highest tier. Registry: NCT02367781 | 3 | Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population (Up to approximately 35 months after first patient enrolled); Overall Survival (OS) in the ITT-WT Population (Up to approximately 35 months after first patient enrolled) 2018-03-15 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (93)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (334)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (108)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (150)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (17)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Appears in other studies (31)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other PD-L1 drugs
Avelumab, Durvalumab, Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), Adebrelimab, Envafolimab and 7 more. Compare all 13 PD-L1 drugs
This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Bladder Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Atezolizumab: this drug | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Avelumab | Approved(overall) | Monoclonal antibody | PD-L1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Enfortumab Vedotin | Approved | Antibody–drug conjugate | Nectin-4 | Partial signal | NCT03474107: Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74) NCT03219333: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4) | |
| Nogapendekin Alfa Inbakicept (Anktiva) | Approved | Protein / enzyme therapeutic | IL-15 superagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Cetrelimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tremelimumab | Phase 3 | Monoclonal antibody | CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Visugromab | Phase 2 | Monoclonal antibody | GDF-15 | Weak signal | NCT06059547: Two primary endpoints, no significance test reported (exploratory). Pathologic complete response: 33.3% nivolumab + visugromab (n=15 evaluable) vs 7.1% nivolumab + placebo (n=14 evaluable). Objective response by RECIST 1.1: 60.0% vs 14.3%. Major pathologic response (secondary): 66.7% vs 21.4%. | |
| MK-3120 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-2005 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| IBC-Ab002 | Phase 1(overall) | Monoclonal antibody | PD-L1 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Tuvutromstat | Phase 1 | Small molecule | MAT2A | not yet graded | No reviewed efficacy summary in this indication | |
| Avipendekin Pegol | —(overall) | Cytokine | IL-15 receptor | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(208 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Atezolizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (26)
November 2026 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
December 2026 (19)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (92)
January 2027 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
February 2027 (4)
What to watch
What to watch
What to watch
What to watch
March 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
April 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
May 2027 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
June 2027 (11)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (14)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
August 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
September 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
October 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
November 2027 (3)
What to watch
What to watch
What to watch
December 2027 (14)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (44)
January 2028 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
February 2028 (4)
What to watch
What to watch
What to watch
What to watch
March 2028 (4)
What to watch
What to watch
What to watch
What to watch
April 2028 (1)
What to watch
June 2028 (1)
What to watch
July 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
August 2028 (2)
September 2028 (3)
What to watch
What to watch
What to watch
October 2028 (4)
What to watch
What to watch
What to watch
November 2028 (3)
What to watch
What to watch
What to watch
December 2028 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (17)
February 2029 (2)
March 2029 (3)
April 2029 (3)
What to watch
What to watch
What to watch
May 2029 (1)
What to watch
June 2029 (2)
July 2029 (1)
What to watch
August 2029 (1)
What to watch
September 2029 (1)
What to watch
October 2029 (3)
What to watch
What to watch
What to watch
2030 (13)
January 2030 (3)
What to watch
What to watch
What to watch
March 2030 (2)
What to watch
What to watch
April 2030 (1)
What to watch
May 2030 (2)
August 2030 (2)
September 2030 (1)
What to watch
2031 (8)
January 2031 (1)
What to watch
February 2031 (1)
What to watch
June 2031 (2)
August 2031 (2)
What to watch
What to watch
November 2031 (1)
What to watch
December 2031 (1)
What to watch
2032 (3)
June 2032 (1)
What to watch
2033 (1)
March 2033 (1)
2035 (1)
May 2035 (1)
What to watch
2040 (3)
February 2040 (1)
What to watch
March 2040 (1)
What to watch
July 2040 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent